Previewing Immunovant’s myasthenia gravis study readout — with all its quirky nuance

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

It’s show-me time for batoclimab, the FcRn-targeting antibody treatment from Immunovant and Roivant Sciences. A consequential Phase 3 study readout is coming before the end of the first quarter.

The study results in patients with generalized myasthenia gravis, a debilitating autoimmune disease, will help determine whether batoclimab — or another, more refined antibody also in Immunovant’s pipeline — can compete against Argenx’s Vyvgart, the current top-selling FcRn-targeting treatment.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Enhancing patient empowerment in plastic surgery through social media

For patients considering or undergoing plastic and reconstructive surgery (PRS) procedures, using social media to gather information and answer questions can enhance patient empowerment –

March 29, 2024

Natural Medicine Advisory Bulletin 11.6: June 14th Subcommittee: Problems with Products – Psychedelic Alpha

This was the question directed to state regulators from the chair of the Natural Medicine Advisory Board’s (“NMAB”) combined subcommittee, Dr. Bradley Conner, during the

June 22, 2024

UAB researchers examine the efficacy of cardiovascular health scores for mortality prediction

Physician-scientists from the University of Alabama at Birmingham Marnix E. Heersink School of Medicine conducted a nationwide study evaluating the predictive value of cardiovascular health

July 23, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.